GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
Overview
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
Source
Originally published at www.marketwatch.com.
Related Articles
- 51% of U.S. adults say the American Dream is out of reach for most people right now: CNBC survey
- A massive 16% market swing just rocked South Korea over 24 hours. The retail ‘ants’ holding the wheel are driving dangerously.
- I’m 60, retired with $3 million. My fiancée, 55, has $1 million but plans to work for the next 10 years. Are we compatible?
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.